Alpha Tau Medical Ltd. Reports Strong Financial Growth in H1 2025

Alpha Tau Medical Ltd ( (DRTS) ) has provided an update.

On August 11, 2025, Alpha Tau Medical Ltd. released its interim consolidated financial statements for the six months ended June 30, 2025. The report highlights an increase in total assets from $86,204,000 to $110,954,000 and a rise in shareholders’ equity from $62,666,000 to $86,623,000. The financial results indicate a positive trajectory for the company, reflecting its ongoing efforts in research and development, as well as its strategic market positioning. These developments may have significant implications for stakeholders, suggesting strengthened financial health and potential growth opportunities in the medical industry.

The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.

Spark’s Take on DRTS Stock

According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.

Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.

To see Spark’s full report on DRTS stock, click here.

More about Alpha Tau Medical Ltd

Alpha Tau Medical Ltd. is a company based in Jerusalem, Israel, operating in the medical industry. The company focuses on developing innovative cancer treatment solutions, with a primary emphasis on utilizing alpha radiation therapy to target and treat tumors.

Average Trading Volume: 48,906

Technical Sentiment Signal: Buy

Current Market Cap: $287.1M

See more insights into DRTS stock on TipRanks’ Stock Analysis page.